Cosette Pharmaceuticals

Privately held: no public share price

Assets

(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
GABA-A receptor (benzodiazepine site)Small molecule
EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome
Colesevelam(Welchol)
Approved
Bile acid sequestrantSmall molecule
Type 2 Diabetes
Approved
Nonsteroidal Anti-inflammatory DrugSmall molecule
Migraine
bremelanotide(Vyleesi)
Phase 2
MC4RPeptide
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 March 2025Topline resultbremelanotideBMT-801 Phase 2 obesity co-administration study meets primary endpoint
Q1 2025Topline resultbremelanotidePhase 2 of bremelanotide with tirzepatide met its primary endpoint

Financial reports

No financial reports recorded.